Last Updated2026-06-02

Market View

₹1,302.6(▲11.23%)

Reporting PeriodQ4 FY26

RUBICONRUBICON Forensic Risk Analysis

Name: RUBICON Structural Risk Analysis
Creator: Flagium AI
License: https://creativecommons.org/licenses/by-nc-nd/4.0/

Pharmaceuticals

Risk ClassStable

Market CapN/A

Primary DriverGovernance

Flagium AI Risk Score

0 / 100

0 QoQ

Stable

Sentinel Insight

Financial profile remains stable for now. Pressure has stabilized in governance. This indicates that forensic pressure is currently receding. No major change in risk trend.

0.0th %ile (Sector)Accel: +0 Qtrs

Updated2026-06-02

Market View

₹1,302.6▲11.23%

PeriodQ4 FY26

Score Waterfall
Absolute contribution points of each forensic pillar to the final risk score. Derived from: Sector Baseline + Active Penalties - Mitigation Buffers.

No active forensic penalties contributing.

Final Composite Risk0 / 100

Investment Risk Thesis

Historical Trend

Current risk score has declined from 0 → 0 over 12 quarters.

Expected Direction

⚠ Watch

Primary Deterioration Drivers

No active triggers

What to Watch Next Quarter

Active Risk Objects (0)

CriticalHigh

Risk Trajectory

Loading Chart

Resilience Matrix

Metric	Value	vs Sector	Signal
Volatility (σ)		7.70	✅ RESILIENT
Sensitivity (ε_s)	1	1.00	✅ RESILIENT
Escalation Prob.	5%	5%	✅ NEUTRAL
Safety Buffer	+66.0	+47.0	✅ RESILIENT

Forensic Benchmark Context: Pharmaceuticals (n=99 peers)

Correlation Analysis
Visualizing the relationship between stock price movement and structural risk objects.

Loading Chart

Share Price

Risk Score (0-100)

Market Performance

₹1,302.6(+11.23%)

1M Divergence+32.03%

1 Week+33.22%

1 Month+34.3%

6 Months+108.65%

1 YearN/A

2 Year+110.73%

3 Year+110.73%

Sector Average (1M)+2.27%

Sentinel Forensic Assessment

ALGORITHMIC RISK PROFILE • NON-ADVISORY

The structural architecture is currently robust. Capital resilience buffers in governance remain well-maintained against forensic benchmarks. Systematic scans of structural transparency and audit trails confirm the absence of material structural stress. The current structural trajectory supports a stable risk outlook.

RUBICON • MARKET STRUCTURE

Stage 1 — Accumulation

The company is in a foundational phase. Risk metrics are stabilizing as the company builds a base for potential future fundamental improvement.

Stage Transition Prob.55%

Trend QualityEarly Base

Phase Progression

Phase Progression Score42.5%

Readiness LabelLow (Early Base Consolidation)

Probability of Advancing55%

CoinTree Momentum

Composite Z-Score+2.9622σ

Strong positive momentum leadership

Universe Rank#37 of 2716

Top 1.36% in momentum strength

Timeframe Sparklines

1W+33.2%

1M+34.3%

6M+108.7%

Weinstein Indicators

150 DMA₹761.76

200 DMA₹N/A

150 DMA SlopeN/ANeutral

Relative Strength+110.16%Leading

Relative Turnover (RTR)1.0000

ParticipationNeutral

PEER COMPARISON

Ranked comparison against sector peers

This company appears relatively stable compared to the Sector Mean (19).

Ticker	Risk Score	Sector %ile	Delta	Flags	Accel	Primary Driver
RUBICONRUBICON	0	0th	0	0	+0	GovernanceStable
ABBOTINDIAABBOTINDIA	0	0th	0	0	+0	GovernanceStable
AARTIDRUGSAarti Drugs Limited	19	51th	-5	11	+0	Competitive PositionStable
AAREYDRUGSAarey Drugs & Pharmaceuticals Limited	23	63th	-5	20	+0	Balance Sheet StressWatch